Completed

NCT Number: NCT01344967

Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect

Bone is the most common site of spread of breast cancer and bone metastases will occur in roughly 70% of women with advanced disease. These patients are at risk of developing bone complications that cause significant impact on both patient morbidity and mortality. Close to two-thirds of women with bone metastases will go on to develop at least one of these complications, termed a skeletal related event (SRE), defined as 1) pathological fractures, 2) pain requiring radiation or surgical intervention, 3)spinal cord compression, and 4) hypercalcemia. In addition to SREs, most breast cancer patients with bone metastases have some degree of pain associated with their disease. Understandably these factors negatively impact their quality of life. Furthermore, the development of an SRE in this population has been shown to be associated with shorter overall survival. Prevention or delay in onset of these complications is therefore an important therapeutic goal.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Breast Cancer With Bone Involvement

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

St. Michael's Hospital

Toronto, Ontario, M5B 1N9, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must have histologically confirmed breast cancer.
Radiological or pathological evidence of bone metastases. (positive bone scan, MRI, or CT or pathological fracture, or pathological sample from bone biopsy showing evidence of metastatic breast cancer).
Patient has not yet started on BP therapy for metastatic breast cancer to bone.
Renal (serum creatinine, BUN), hepatic (AST, ALT, Bilirubin) function within the institutional normal range as assessed within 1 month of study entry.
Age >/= 18 years.
Karnofsky performance status ≥ 50.
Life expectancy > 6 months.
Ability to understand and the willingness to sign a written informed consent document.
Patients may receive any chemotherapy, biological or endocrine treatment considered appropriate by the treating physician. This can be changed during the course of the study as clinically indicated.
Patients may be on another clinical trial, if allowed by the Trial Steering Committee for that trial.
Patients are willing to take calcium and vitamin D supplements as recommended, while on study.

Exclusion criteria

Hypersensitivity or known allergy to bisphosphonates.
Patient currently taking Bisphosphonate therapy for metastatic breast cancer to bone (Clodronate, Pamidronate, Zoledronic Acid, Ibandronate, Calcitonin). Bisphosphonates for the treatment of other bone disease (osteoporosis, osteopenia, Paget's disease, etc) but not Zoledronic Acid, are permitted.
Acute or chronic renal insufficiency.
Hypocalcemia as defined by serum calcium less than institutional normal range.
Evidence of infection/abscess on dental exam or recent dental extraction (within last 4 weeks), or presence of osteonecrosis of the jaw.
Acute pathological fracture, spinal cord compression, or hypercalcemia requiring urgent treatment (patient may enter study after acute issues are resolved).
Patients with baseline hypocalcemia.
Patients who have received ZA for prevention of breast cancer treatment-induced osteopenia or osteoporosis within the last 1 year.
History and/or electrocardiographic evidence of atrial fibrillation.
Pregnancy or lactation.

Treatment and study plan

Zoledronic acid

Drug

Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline

Other names: Control No. 110322

Primary outcomes

The primary objective of this study is to estimate the proportion of patients with suppression of bone turnover at 12 weeks after administration of a single dose of Zoledronic Acid

Time frame: Baseline to Twelve weeks

Secondary outcomes

To estimate the distribution of duration of suppression of bone turnover up to 12 weeks after administration of Zoledronic Acid

Time frame: Baseline to Twelve weeks

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

Canadian Breast Cancer Foundation

Registry information

Acronym: SuBDuE

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Apr 29, 2011
Registry last updated: Jun 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.